Sotuletinib Dihydrochloride

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF-1R; CSF1R), with potential antineoplastic activity. CSF1R inhibitor BLZ945 selectively binds to CSF1R expressed on tumor-associated macrophages (TAMs), blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways. This inhibits the activity and proliferation of TAMs, and reprograms the immunosuppressive nature of existing TAMs. Altogether, this reduces TAM-mediated immune suppression in the tumor microenvironment, re-activates the immune system, and improves anti-tumor cell responses mediated by T-cells. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand, colony stimulating factor 1 (CSF1); this receptor is overexpressed by TAMs in the tumor microenvironment, and plays a major role in both immune suppression and the induction of tumor cell proliferation.

**Synonyms:** - 2-Pyridinecarboxamide, 4-((2-(((1r,2r)-2-Hydroxycyclohexyl)amino)-6-Benzothiazolyl)oxy)-N-methyl-, Hydrochloride (1:2) - BLZ 945 Dihydrochloride - BLZ-945 Dihydrochloride - BLZ945 Dihydrochloride - SOTULETINIB DIHYDROCHLORIDE